Mizuho raised the firm’s price target on ResMed (RMD) to $290 from $270 and keeps an Outperform rating on the shares. The firm sees no evidence of weight loss drug shares losses for ResMed in its quarterly report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD:
- ResMed price target raised to $270 from $240 at Stifel
- ResMed price target raised to $270 from $248 at Piper Sandler
- ResMed price target raised to $305 from $283 at Baird
- ResMed price target raised to $325 from $285 at UBS
- Resmed’s Strong Financial Performance and Strategic Growth Initiatives Drive Buy Rating